
Laurus Labs Q2 Results 2025 Highlights: Net Profit Rises by 882.71% & Revenue Up 35.12% YoY
Click and Sign Up to Get Live Updates on Q2 Results
Updated: 24 Oct 2025 • 5:14 pm
Posted by:

Laurus Labs Q2 Results FY26: During Q2 FY26, Laurus Labs’ profit increased 882.17% YoY, while revenue increased by 35.12% YoY. The company posted robust numbers, with Q2 PAT at ₹194.97 crores and revenue at ₹1,653.47 crores. Laurus Labs showed its Q2 results on 23rd October 2025.
Laurus Labs Q2 Results FY26: Extracts of FY25 & FY26
| Particulars | Consolidated Figures | Standalone Figures | ||
| 30th Sep 2025 | 30 Sept 2024 | 30th Sept 2025 | 30th Sept 2024 | |
| Revenue from Operations | ₹1,653.47 | ₹1,223.70 | ₹1,566.50 | ₹1,184.85 |
| Profit Before Tax (PBT) | ₹430.22 | ₹182.93 | ₹418.11 | ₹193.72 |
| Profit After Tax (PAT) | ₹194.97 | ₹19.84 | ₹215.67 | ₹42.44 |
Laurus Labs Q2 Results FY26 Highlights (Q2 FY26 vs FY25)
- Laurus Labs clocked Q2 FY26 consolidated revenue of ₹1,653.47 crores vs ₹1,223.70 crores.
- On the profit front, Laurus Labs earned a consolidated PAT of ₹194.97 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹19.84 crore.
- According to the consolidated figures, Laurus Labs’ quarterly PAT increased by 882.17% YoY, while revenue increased by 35.12%.
- Laurus Labs clocked Q2 FY26 standalone revenue of ₹1,556.50 crores vs ₹1,184.85 crores.
- On the profit front, Laurus Labs earned a standalone PAT of ₹215.67 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹42.44 crore.
- According to the standalone figures, Laurus Labs’ quarterly PAT increased by 408.18% YoY, while revenue increased by 32.22%.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
About Laurus Labs Limited
Laurus Labs was established in 2005, with its headquarters in Hyderabad. Laurus Labs is an integrated pharmaceutical and biotechnology company. The company operates across four main business areas, including Active Pharmaceutical Ingredients (APIs), which includes a leadership position in anti-retrovirals (ARVs), Hepatitis, and oncology. The company has a global presence and focuses on providing affordable and high-quality pharmaceutical solutions through its research-driven approach and compliant manufacturing facilities.
Laurus Labs Share Price Performance
On the opening bell on 24th October 2025, Laurus Labs shares opened at ₹939.75 per share. However, the initial gains have since eroded, and Laurus Labs shares are trading at ₹923.35 per share, below the opening price.
Considering the long-term achievements, Laurus Labs shares have yielded close to 43.04% returns in the past 6 months, and 1-year returns stand at 106.43%. Over the maximum timeframe, Laurus Labs shares delivered a 873.51% return to investors.
What Analysts Expect Post Q2 Results?
Following robust Q2 results from Laurus Labs, analysts expect its share price to rise. According to analysts, Laurus Labs’ share price could reach ₹998.40 per share in the coming year and, in a downturn, could hit ₹915.30 per share. However, one must ignore stock market volatility and invest in Laurus Labs’ shares after thorough research.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY
Inspira Enterprise India IPO Details: Everything You Should Know about
Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY
HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY
BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here
Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here
Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here
Recent Articles

Supreme Engineering Share Analyst Review: CMP, Performance, Target and 2026 Outlook
5 June 2026

Super Spinning Mills Share Analyst Review: CMP, Performance, Target and 2026 Outlook
5 June 2026

Transwarranty Finance Share Analyst Review: CMP, Performance, Target and 2026 Outlook
5 June 2026

Suraj Share Analyst Review: CMP, Performance, Target and 2026 Outlook
5 June 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Supreme Engineering Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Super Spinning Mills Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Transwarranty Finance Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Suraj Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Supreme Holdings & Hospitality (India) Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Popular this week
Supreme Engineering Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Super Spinning Mills Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Transwarranty Finance Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Suraj Share Analyst Review: CMP, Performance, Target and 2026 Outlook
Supreme Holdings & Hospitality (India) Share Analyst Review: CMP, Performance, Target and 2026 Outlook

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





